ABOUT THE TEAM

Stephen T. Sonis, D.M.D., D.M.Sc.
Founder, Partner, Chief Scientific Officer

Dr. Sonis is a senior academic and research scientist who holds appointments at the Harvard School of Dental Medicine (HSDM), the Dana-Farber Cancer Institute (DFCI), and Brigham and Women’s Hospital (BWH). After receiving his DMD from Tufts, Dr. Sonis completed a combined doctorate and specialty training program at Harvard and was a Knox Fellow at Oxford (UK) where he studied tumor immunology. In addition to his academic appointments, Dr. Sonis is the Chief Scientific Officer of Biomodels, LLC; Co-Founder and Chief Scientific Advisor of Inform Genomics; Past president of TRIAD Burden of Illness Studies, a not-for-profit company focusing on the adverse health and economic outcomes of cancer toxicities.

Gregory D. Lyng, Ph.D.
Founder, Partner, Chief Operations Officer

As a co-founder of PES, Dr. Lyng is responsible for the oversight of all PES research collaborations.  Additionally, he works closely with PES clients to ensure proper design and utilization of EdQ™ management.  Dr. Lyng’s scientific expertise lies in translational research spanning the areas of inflammatory disease, cancer supportive care, oncology, and diseases of the central nervous system.  Dr. Lyng received his Ph.D. in Biomedical Sciences from the University at Albany School of Public Health and his B.S. in Neuroscience from St. Lawrence University.  In addition to his role at PES, Dr. Lyng is the Chief Operating Officer at Biomodels, LLC where he is responsible for the oversight of their preclinical/translation research programs.

Daniel S. Lichtman
Founder, Managing Partner

Mr. Lichtman has been the Managing Partner at Biomodels since 2012. Following sales and marketing positions at Abbott, J+J and Bayer, He recognized opportunities presented by advances in medical technology and founded an in-vitro diagnostic instrumentation company when diagnostics was in its infancy and its distribution was an unsophisticated part of hospital supply. Additionally, Mr. Lichtman saw drug discovery as synergistic with diagnostics and founded a contract research organization. The success of both companies reflects Mr. Lichtman's commitment to innovation and excellence. He brings his management skills as a CEO and his commitment to translational research to Biomodels to amplify the corporate philosophy of an employee-centric culture.

Catherine Trewin, CPA, CA
Founder, Partner, Chief Financial Officer

As a co-founder of Primary Endpoint Solutions, Ms. Trewin serves as its Chief Financial Officer. Ms. Trewin also provides leadership at Biomodels as its Chief Financial Officer, bringing her extensive experience with pre-clinical research and medical diagnostic instrumentation companies, including Inter-Medico, NoAb BioDiscoveries, and LabOne. In addition, she has held public accounting and other industry positions at KPMG, Ernst Young and Avery Dennison. Ms. Trewin holds a Bachelor of Commerce degree from the University of Toronto and is a member of Canadian Institute of Chartered Accounts and holds a CPA, CA designation.

Contact us today to reduce risk and improve your results.
About Primary Endpoint Solutions​

PES’s integrated services eliminate inconsistent and incomplete trial data, ensuring that the selection, capture, accuracy, and analysis of endpoints is optimized.

© Copyright Primary Endpoint Solutions 2019

Contact​

313 Pleasant Street

Watertown, MA 02472

info@pesclinical.com